Navigation Links
RXi Pharmaceuticals Announces Positive Data in Second Phase 1 Multi-Dose Study

WESTBOROUGH, Mass., July 12, 2013 /PRNewswire/ -- RXi Pharmaceuticals Corporation (OTCQX: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced positive results from their second placebo-controlled Phase 1 study with RXI‑109, an sd-rxRNA® compound that targets Connective Tissue Growth Factor (CTGF), and is being developed for the treatment of abnormal dermal scars such as hypertrophic scars and keloids in conjunction with scar revision surgery.

In this study, subjects received small skin incisions in their abdomen and were treated with 3 intradermal doses of RXI‑109 over a 2-week period.  This dose escalating study consisted of 3 cohorts of 3 healthy volunteers each.  Subjects received RXI‑109 on one side of the abdomen, and placebo on the other side. Subjects were monitored for safety and local and systemic side effects over a total study period of 84 days. Multiple dermal injections were well tolerated at all doses, and treatment with RXI‑109 resulted in dose-dependent silencing of CTGF mRNA in the treated areas.

Dr. Geert Cauwenbergh, President and CEO of RXi Pharmaceuticals said that, "We are very pleased with the outcome of this second Phase 1 study.  These results show that multiple intradermal injections of RXI‑109 are well tolerated with minimal and mild side effects. He added that, "The work done in the last year has confirmed that our proprietary self-delivering RNAi technology (sd-rxRNA) reduces CTGF mRNA in humans in line with its mechanism of action. Indeed, results from this second study demonstrate that mRNA for CTGF in the incisions is reduced in a dose-dependent manner by RXI‑109 as compared to placebo. Our first Phase 1 study had already shown that a single dose of the drug lowered the actual protein content for CTGF also in a dose-dependent manner. With this exciting outcome, we are ready to embark on Phase 2 development in patients with hypertrophic scars and keloids."

About RXi Pharmaceuticals Corporation

RXi Pharmaceuticals Corporation (OTC: RXII) is a biotechnology company focused on discovering, developing and commercializing innovative therapies based on its proprietary, self-delivering RNAi platform. Therapeutics that use RNA interference, or "RNAi," have great  promise because of their ability to down-regulate, the expression of a specific gene that may be over-expressed in a disease condition. Building on the pioneering work of scientific founder and Nobel Laureate Dr. Craig Mello, a member of the RXi Scientific Advisory Board, RXi's first RNAi product candidate, RXI‑109, targets connective tissue growth factor (CTGF) to reduce dermal scarring (fibrosis), entered into human clinical trials in June 2012.  For more information, please visit

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about future expectations, planned and future development of RXi Pharmaceuticals Corporation's products and technologies. Forward-looking statements about expectations and development plans of RXi's products involve significant risks, and uncertainties: risks that RXi may not be able to successfully develop its candidates, or that development of RNAi-based therapeutics may be delayed or not proceed as planned, or that we may not develop any RNAi-based product; risks that the development process for our product candidates may be delayed, risks related to development and commercialization of products by our competitors, risks related to our ability to control timing and terms of collaborations with third parties, and the possibility that other companies or organizations may assert patent rights preventing us from developing our products. Actual results may differ from those contemplated by these forward-looking statements. RXi does not undertake to update forward-looking statements to reflect a change in its views, events or circumstances that occur after the date of this release.

SOURCE RXi Pharmaceuticals Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. UCBs Kremers Urban Pharmaceuticals Inc. receives FDA approval for extended release methylphenidate hydrochloride
2. Tris Pharmas Generic Pharmaceuticals Business Launches Dextroamphetamine Sulfate Oral Solution
3. Breckenridge Announces Dismissal of Various Lawsuits Against Macoven Pharmaceuticals in Return for Macovens Discontinuance of Certain Products
4. Kinex Pharmaceuticals Will Take the Lead in the Orascovery Program Development in China
5. Actinium Pharmaceuticals Clinical Results Featured at a United Nations Forum
6. Vanda Pharmaceuticals to Participate in Upcoming Investor Conferences
7. Vanda Pharmaceuticals, Inc. Sued by Investor
8. Avanir Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
9. Valeant Pharmaceuticals Announces Closing of Public Offering of Common Shares
10. Anthera Pharmaceuticals Announces Receipt of Nasdaq Notice
11. Oramed Pharmaceuticals to Present Findings on Oral Insulin to the American Diabetes Association
Post Your Comments:
(Date:12/1/2015)... och UPPSALA, Sverige, December 1, 2015 ... International Breast Cancer Study Group (IBCSG, ... Bryssel) att ingå i en klinisk studie av ... --> --> Studien, med namn ... behandlas med anti-hormonella läkemedel i kombination med palbociclib, ...
(Date:11/30/2015)... Minn. and BASEL, Switzerland ... Laboratories, Inc. (Upsher-Smith), through its wholly-owned UK subsidiary ... further development of a novel, oral small molecule inhibitor ... that may be effective in the treatment of inflammatory ... clinical development. --> --> ...
(Date:11/30/2015)... 1, 2015 Express Scripts (NASDAQ: ESRX ) ... IMMY ) to drive access to a low-cost alternative to ... toxoplasmosis that has been recently priced out of reach for ... systems. --> --> Imprimis ... (a form of folic acid) for $1 per capsule for people ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... November 30, 2015 , ... Third Molar SEO ... it has officially launched a sleek, mobile-ready and user-centric redesigned website. , Vivek ... website clearly outlines the benefits that its SEO services provide to dentists and ...
(Date:11/30/2015)... ... 2015 , ... Trevor and Taylor Crabb have unveiled an exciting new ... represent the United States. This hybrid crowdfunding campaign is designed to provide ... in addition to offering corporate sponsors with some great marketing deliverables with the brothers ...
(Date:11/30/2015)... , ... December 01, 2015 , ... ... Christina Colon as a 2015-2016 inductee into its VIP Woman of the ... NAPW is the nation’s leading networking organization exclusively for professional women, boasting 850,000 ...
(Date:11/30/2015)... ... December 01, 2015 , ... The National Association ... inductee into its VIP Woman of the Year Circle. She is recognized with ... organization exclusively for professional women, boasting 850,000 members and over 200 operating Local ...
(Date:11/30/2015)... ... December 01, 2015 , ... Live Very Well is ... insurance plans on . The multi-carrier insurance exchange platform offers individual ... allowing consumers to compare, quote and match plans to meet their needs. ...
Breaking Medicine News(10 mins):